- Home
- TRTX vs XERS Comparison
TRTX vs XERS Comparison
Compare TRTX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRTX
- XERS
- Stock Information
- Founded
- TRTX 2014
- XERS 2005
- Country
- TRTX United States
- XERS United States
- Employees
- TRTX N/A
- XERS N/A
- Industry
- TRTX Real Estate Investment Trusts
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- TRTX Real Estate
- XERS Health Care
- Exchange
- TRTX Nasdaq
- XERS Nasdaq
- Market Cap
- TRTX 632.5M
- XERS 752.7M
- IPO Year
- TRTX 2017
- XERS 2018
- Fundamental
- Price
- TRTX $8.49
- XERS $5.02
- Analyst Decision
- TRTX Buy
- XERS Strong Buy
- Analyst Count
- TRTX 3
- XERS 6
- Target Price
- TRTX $9.00
- XERS $6.25
- AVG Volume (30 Days)
- TRTX 641.5K
- XERS 2.0M
- Earning Date
- TRTX 07-29-2025
- XERS 08-07-2025
- Dividend Yield
- TRTX 11.31%
- XERS N/A
- EPS Growth
- TRTX N/A
- XERS N/A
- EPS
- TRTX 0.70
- XERS N/A
- Revenue
- TRTX $148,005,000.00
- XERS $222,551,000.00
- Revenue This Year
- TRTX N/A
- XERS $35.31
- Revenue Next Year
- TRTX $9.19
- XERS $19.65
- P/E Ratio
- TRTX $12.15
- XERS N/A
- Revenue Growth
- TRTX N/A
- XERS 29.88
- 52 Week Low
- TRTX $6.47
- XERS $2.10
- 52 Week High
- TRTX $9.32
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- TRTX 67.12
- XERS 51.52
- Support Level
- TRTX $8.01
- XERS $4.99
- Resistance Level
- TRTX $8.28
- XERS $5.22
- Average True Range (ATR)
- TRTX 0.16
- XERS 0.23
- MACD
- TRTX 0.03
- XERS -0.02
- Stochastic Oscillator
- TRTX 99.05
- XERS 43.37
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).